Antibodies to the Spike Protein Receptor-Binding Domain of SARS-CoV-2 at 4–13 Months after COVID-19
Authors:
- Evgeniia A. KolosovaEvgeniia A. Kolosova
- Olga N. ShaprovaOSOlga N. Shaprova
- Daniil V. ShanshinDSDaniil V. Shanshin
- Valentina S. NesmeyanovaVNValentina S. Nesmeyanova
- Iuliia A. MerkulevaIMIuliia A. Merkuleva
- Svetlana V. BelenkayaSBSvetlana V. Belenkaya
- Anastasiya A. IsaevaAIAnastasiya A. Isaeva
- Artem O. NikitinANArtem O. Nikitin
- Ekaterina A. VolosnikovaEVEkaterina A. Volosnikova
- Yuliya A. NikulinaYNYuliya A. Nikulina
- Marina A. NikonorovaMNMarina A. Nikonorova
- Dmitry N. ShcherbakovDSDmitry N. Shcherbakov
Open Access
- 13 July 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4053
Abstract
Identification of factors behind the level and duration of persistence of the SARS-CoV-2 antibodies in the blood is assumed to set the direction for studying humoral immunity mechanisms against COVID-19, optimizing the strategy for vaccine use, antibody-based drugs, and epidemiological control of COVID-19. Objective: This study aimed to study the relationship between clinical and demographic characteristics and the level of IgG antibodies to the RBD of SARS-CoV-2 spike protein after COVID-19 in the long term. Residents of the Altai Region of Western Siberia of Russia, Caucasians, aged from 27 to 93 years (median 53.0 years), who recovered from COVID-19 between May 2020 and February 2021 (n = 44) took part in this prospective observational study. The titer of IgG antibodies to the RBD of SARS-CoV-2 spike protein was measured repeatedly in the blood at 4–13 months from the beginning of the clinical manifestation of COVID-19 via the method of enzyme-linked immunosorbent assay. The antibody titer positively correlated with age (p = 0.013) and COVID-19 pneumonia (p = 0.002) at 20–40 and 20–24 weeks from the onset of COVID-19 symptoms, respectively. Age was positively associated with antibody titer regardless of history of COVID-19 pneumonia (beta regression coefficient p = 0.009). The antibody titer decreased in 15 (34.1%) patients, increased in 10 (22.7%) patients, and did not change in 19 (43.2%) patients from the baseline to 48–49 weeks from the onset of COVID-19 symptoms, with seropositivity persisting in all patients. Age and COVID-19 pneumonia are possibly associated with higher IgG antibodies to the spike protein RBD of SARS-CoV-2 following COVID-19 in the long term. Divergent trends of anti-RBD IgG levels in adults illustrate inter-individual differences at 4–13 months from the onset of COVID-19 symptoms.Keywords
Funding Information
- Presidential Scholarship of the Russian Federation (SP-5107.2021.4)
This publication has 32 references indexed in Scilit:
- COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domainJournal of Clinical Investigation, 2020
- Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 BindingmSphere, 2020
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesNature, 2020
- COVID-19 and the Path to ImmunityJAMA, 2020
- Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 SpikeCell Reports Medicine, 2020
- Distinct Early Serological Signatures Track with SARS-CoV-2 SurvivalImmunity, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Fatal Cases of Seasonal Influenza in Russia in 2015–2016PLOS ONE, 2016
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951